Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?Simplywall·Jul 28 at 02:13 PM02142+4.19%01099-1.53%
Hong Kong's Niche Sectors Signal Structural Shifts: How Institutions Are RepositioningGlobal Report·Jul 28 at 04:13 AM01099-1.53%01513-0.38%
HBM Holdings enters strategic biologics R&D collaboration with SinopharmPUBT·Jul 27 at 04:00 AM01099-1.53%02142+4.19%
The Great Unbundling: How AI Infra and Defensive Yields Are Reshaping a Fragmented Hong Kong MarketGlobal Report·Jul 24 at 04:13 AM02866+1.09%82388-0.31%
Hong Kong Equities Parse Divergent Earnings Signals Across SectorsGlobal Report·Jul 22 at 04:17 AM01179-1.89%02333-2.89%
The Revaluation of Niche HK Stocks: 10 Tech and Manufacturing Leaders to WatchGlobal Report·Jul 21 at 04:25 AM07666+4.25%06651+11.95%
Capital Reallocation in Hong Kong: Earnings Divergence and the Rush for Hedging ToolsGlobal Report·Jul 18 at 04:12 AM01099-1.53%
Sinopharm Group slips 1.4% to HK$15.94, hits 52-week lowHK Stock Market Update·Jun 29 at 10:32 PM01099-1.53%
Valuation Reboot: Tracking the Tectonic Shifts Across 82 Key HK & US EquitiesGlobal Report·Jun 23 at 04:15 AM01929+2.23%06862-0.59%
Sinopharm Sets Final 2025 Dividend and Clarifies Withholding Tax for H-Share InvestorsTip Ranks·Jun 18 at 04:43 AM01099-1.53%
Sinopharm declares final dividend of RMB 0.69 a share for FY2025PUBT·Jun 18 at 04:05 AM01099-1.53%000028+0.10%
